Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 1011-1016

  Marey, Hatem M ^a   Ellakwa, Amin F ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

Author keywords

Central macular thickness; Intraocular pressure; Ivb; Ivt; Visual acuity

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG EFFICACY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; RETINA MACULA LUTEA; THICKNESS; TREATMENT RESPONSE; VISUAL ACUITY;

EID: 79961231326     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S22103     Document Type: Article

References (23)

1. Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology. 1984;91:1-9.
2. Hardy RA, Crawford JB. Retina. In: Vaughn D, Asbury T, Riordan-Eva P, editors. General Ophthalmology. 15th ed. Stamford, CT: Appleton and Lange; 1999:178-199.
3. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Arch Ophthalmol. 1985;103: 1796-1806.
4. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema: long-term visual results. Ophthalmology. 1991; 98:1594-1602.
5. Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: threemonth efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology. 2004;111:2044-2049.
6. Audren F, Erginay A, Haouchine B, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmol Scand. 2006;84: 624-630.
7. Chun DW, Heier JS, Topping TM, et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology. 2006;113:1706-1712.
8. Sears JE, Hoppe G. Triamcinolone acetonide destabilizes VEGF mRNA in Muller cells under continuous cobalt stimulation. Invest Ophthalmol Vis Sci. 2005;46:4336-4341.
9. Gardner TW, Antonetti DA, Barber AJ, et al. Penn State Retina Research Group. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol. 2002;47:S253-S256.
10. Shulman S, Ferencz JR, Gilady G, Ton Y, Assia E. Prognostic factors for visual acuity improvement after intravitreal triamcinolone injection. Eye (Lond). 2007;21(8):1067-1070.
11. Tewari HK, Sony P, Chawla R, et al. Prospective evaluation of intravitreal triamcinolone acetonide injection in macular edema associated with retinal vascular disorders. Eur J Ophthalmol. 2005;15: 619-626.
12. Gregori NZ, Rosenfeld PJ, Puliafito CA, et al. One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Retina. 2006;26:889-895.
13. Konstantopoulos A, Williams CP, Newsom RS, Luff AJ. Ocular morbidity associated with intravitreal triamcinolone acetonide. Eye (Lond). 2007;21(3):317-320.
14. Ricci F, Missiroli F, Parravano M. Argon laser trabeculoplasty in triamcinolone acetonide induced ocular hypertension refractory to maximal medical treatment. Eur J Ophthalmol. 2006;16:756-757.
15. Thompson JT. Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am J Ophthalmol. 2006;141:629-637.
16. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
17. Funatsu H, Yamashita H, Ikeda T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2003;110:1690-1696.
18. Funatsu H, Yamashita H, Ikeda T, et al. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol. 2002;133:537-543.
19. Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci. 2001;42:2408-2413.
20. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996;103: 1820-1828.
21. Cunningham ET Jr, Adamis AP, Altaweel M, et al. Macugen Diabetic Retinopathy Study Group. A Phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112:1747-1757.
22. Soheilian M, Ramezani A, Bijanzadeh B, et al. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina. 2007;27:1187-1195.
23. Ahmadieh H, Ramezani A, Shoeibi N, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, readomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2008;246:483-489.